New cutting edge research into drug treatments will soon begin in Dundee following an £8m investment by the Scottish government.
The money has been awarded to the Scottish Universities Life Sciences Alliance and will fund the UK National Phenotypic Screening Centre, a state-of-the-art robotic drug treatment lab called based at the University of Dundee. Phenotypic screening is a form of biological research which studies how drugs affect organisms at a cellular level and the research led at the university’s College of Life Sciences will aim to build on recent advances in genetic engineering, stem cell technology and cell and organ culture systems to help develop new drugs.
Cabinet secretary Michael Russell announced the funding and said that this latest investment would put Scottish universities at the forefront of drug discovery worldwide.
As well as hosting the centre, the University of Dundee will work with some of the top pharmaceutical companies in Europe to form a large public-private partnership in the field of novel therapy research and development.
This new venture will build on the ground-breaking work already carried out by the University of Dundee’s Drug Discovery Unit in developing more effective treatments for some of the world’s most neglected diseases. Founded in 2006, the DDU brings together chemists, physicists, academics and industry scientists to identify drug candidates, lead compounds and innovative tools and approaches across a wide range of debilitating and deadly diseases. The DDU is targeting diseases in the developing world such as Malaria and Tuberculosis and is collaborating with world-class life sciences researchers to develop new approaches to diseases such as Cancer, Diabetes and Alzheimer’s disease.
The new UK National Phenotypic Screening Centre will enable this vital research into tackling diseases to take even greater strides forward.
We hope you’ve enjoyed reading this article. If you’d like to find out how Lifecore Consulting can help your business, please get in touch with us.